Do you think Pfizer's 43B acquisition of Seagen is a threat?
Seagen is a leading developer of medicine called antibody-drug conjugates, or ADCs, which are designed to kill cancer cells and spare healthy ones. ADCs use antibodies to deliver small molecule drugs directly to a tumor site, which may reduce side effects and offer greater efficacy, according to Seagen’s website.
Davis reiterated that Merck is interested in deals between $1-15 billion, with the $10 billion-plus range being the sweet spot. The likes of Prometheus and Acceleron fell in this range and that's “still the size of deals we are very interested in,” he said.
Great list of interesting factors to keep in mind Flipper.
I am aware of the benefits and opportunity with PLX-3397, and it was one of my earliest topics here relating to NWBO and Daiichi. But I was not aware that it is a key constituent in this cocktail. What is the source for this?
“9. PLX-3397 is a key constituent in UCLA cocktail DCvax-l + plc-3397 + poly-iclc and sometimes Keytruda.”